Granulomatosis with polyangiitis (GPA) is a small vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies (C-ANCA), specifically proteinase 3 (PR3) ANCA. GPA classically presents with multi-organ involvement. The first description of GPA defined a triad of features: 1) systemic necrotizing angiitis, 2) necrotizing inflammation of the respiratory tract and 3) necrotizing glomerulonephritis.1 Few cases of digital…
Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.
Dr. Jens Thiel provided a detailed overview of specific treatments for patients with immunoglobulin A (IgA) vasculitis and IgA nephropathy, highlighting treatments in early clinical trials.
At the end of 2023, the Society for Cardiovascular Pathology (SCVP) published consensus guidelines on the diagnostic approach to temporal artery biopsy.1 Through this publication, SCVP hopes to bring more uniformity to the processing, interpretation and reporting of these specimens, taking into consideration the most up-to-date literature available. These guidelines have obvious impact on clinical…
The FDA has approved tocilizumab-aazg (Tyenne), the first tocilizumab biosimilar, for treating rheumatic diseases, as well as the new drug application for CB-101, a chimeric antigen receptor T cell therapy, for treating lupus nephritis and extra-renal lupus.
“As a resident, [I] felt pretty terrible when [we had] a very sick child and the teams [couldn’t] agree on what to do,” said Lauren Henderson, MD, MMS, on an episode of ACR on Air. She discussed the importance of collaboration across specialties in the identification and treatment of macrophage activation syndrome (MAS).
Hoy et al. sought to evaluate the presence, clinical associations, and potential mechanistic roles of circulating calprotectin in a cohort of patients with primary antiphospholipid syndrome (APS) and those with antiphospholipid antibodies. Calprotectin levels were higher in patients with primary APS and those with antiphospholipid antibodies than in healthy controls. These data suggest that calprotectin has the potential to be a functional biomarker and a new therapeutic target for APS-related thrombocytopenia.
Background/Purpose It has been reported that 20–50% of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). The natural history of ultrasound-defined subclinical GCA in PMR is not known. Methods Twenty-five newly diagnosed PMR patients who met a clinical diagnosis for PMR, verified by two rheumatologists, were examined by ultrasound. All six branches…
SAN DIEGO—Panelists at ACR Convergence 2023 debate the merits of IL-6 inhibitors vs. glucocorticoids for the initial treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
SAN DIEGO—The large vessel vasculitides, including Takayasu’s arteritis and giant cell arteritis, experienced a surge of interest at ACR Convergence 2023. Here, we highlight important points from 10 of the studies presented at this conference.